Mednet Introduces TrialMatch: Revolutionizing Cancer Clinical Trial Discovery for Oncologists

Mednet Enhances Oncology Care with Innovative TrialMatch Tool

In an exciting development for oncology, Mednet has recently unveiled TrialMatch, a sophisticated clinical trial discovery tool created to expedite the identification of relevant cancer trials for oncologists. This initiative is made possible through a $2 million contract from the National Cancer Institute (NCI) under the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. The primary goal of TrialMatch is to enable oncologists to pinpoint appropriate trials for their patients in a matter of minutes rather than hours, effectively streamlining the clinical trial enrollment process.

The Urgent Need for Clinical Trial Matching

The scarcity of patient enrollment in clinical trials has long been a significant hurdle in oncology. Data indicates that nearly 20% of trials prematurely close due to inadequate enrollment rates, while a staggering 93% of adults facing cancer never take part in such trials. Many eligible patients remain unidentified simply because the process of locating suitable trials is complex and burdensome. Physicians often have to sift through intricate eligibility criteria and registries that cater more to researchers than to frontline clinicians. TrialMatch seeks to alleviate this problem by facilitating a more straightforward approach to trial discovery.

How TrialMatch Works

Leveraging artificial intelligence, TrialMatch allows oncologists to describe patient profiles in natural language, tailoring the search for open trials based on various factors including diagnosis, cancer stage, biomarkers, and geographical location. The tool provides physicians with detailed match rationales as well as enrollment links to enhance decision-making within their existing workflows. This seamless integration is crucial, as it allows doctors to evaluate potential trial opportunities without diverting their attention from patient care.

In addition, TrialMatch operates within Mednet's extensive physician community. Here, oncologists can engage in discussions, ask questions about challenging cases, and share insights with peers, thereby surfacing relevant enrolling trials amidst over 22,000 conversations centered on complex clinical queries.

Insights from Leadership

"Finding the right clinical trial shouldn't require physicians to step away from patient care and search through multiple databases," stated Dr. Nadine Housri, Co-founder and Chief Medical Officer of Mednet. She emphasized that enabling trial discovery within the natural rhythm of clinical practice is essential to improving trial accessibility for patients. The convergence of oncologists and available trial data through TrialMatch creates new avenues for patient participation, effectively bridging a long-existing gap.

Over 45,000 physicians across 23 specialties currently utilize Mednet, allowing for a community where clinical dialogue thrives, and insights can be easily exchanged.

Future Prospects with TrialMatch

Funding from the NCI SBIR/STTR contract also supports an upcoming evaluation of TrialMatch in partnership with the SWOG Cancer Research Network. This investigation aims to assess whether AI-assisted trial matching enhances physician awareness and improves overall patient enrollment. SWOG has a rich history of conducting influential clinical trials in oncology and this collaboration aligns with its commitment to scientific validation.

TrialMatch is now available at no cost to oncologists, further democratizing access to crucial cancer trials and ultimately aiming to improve patient outcomes across the board. By developing such innovative technologies, Mednet not only advocates for better clinical practices but also nourishes the potential for life-saving advancements in cancer treatment.

Conclusion

With the launch of TrialMatch, Mednet takes a significant step forward in the integration of technology into the healthcare landscape, promising to make clinical trial enrollment more achievable for both oncologists and their patients. As more physicians leverage this tool, the hope is that trial participation rates will rise, leading to faster and more efficient breakthroughs in cancer treatment. The medical community eagerly anticipates the impacts of this advancement on patient care and research at large.